Livingston Manor Care Center | |
939 East Birch, Chillicothe, Missouri 64601 | |
(660) 646-5177 | |
Name | Livingston Manor Care Center |
---|---|
Location | 939 East Birch, Chillicothe, Missouri |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 94 |
Occupancy Rate | 32.87% |
Medicare ID (CCN) | 265621 |
Legal Business Name | Livingston Manor Inc |
Ownership Type | For Profit - Corporation |
NPI Number | 1740385228 |
Organization Name | LIVINGSTON MANOR INC |
Doing Business As | LIVINGSTON MANOR CARE CENTER |
Address | 939 E Birch Dr, Chillicothe, MO 64601 |
Phone Number | 660-646-5177 |
News Archive
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
People who take more than four doses of medicine a day appear more likely to crush tablets or open capsules potentially reducing their effectiveness, QUT research has found.
Scientists have captured new images of a calcium-shuttling molecule that has been linked to aggressive cancers. The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
The team, led from Great Ormond Street Hospital (GOSH), UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and the Istituto Zooprofilattico Sperimentale delle Venezie (Legnaro, Italy), have built on recent advances to grow 'mini-organs' in a laboratory, known as organoids.
A number of new technologies and surgical techniques promise to "personalize" orthopedic operations such as hip and knee replacement, according to research to be presented at an educational program at Hospital for Special Surgery on October 15 and 16. During "Computer Assisted Orthopaedic Surgery: Review of Emerging Technologies," prominent orthopedic researchers will discuss how innovative technologies can improve surgical outcomes.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
People who take more than four doses of medicine a day appear more likely to crush tablets or open capsules potentially reducing their effectiveness, QUT research has found.
Scientists have captured new images of a calcium-shuttling molecule that has been linked to aggressive cancers. The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
The team, led from Great Ormond Street Hospital (GOSH), UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and the Istituto Zooprofilattico Sperimentale delle Venezie (Legnaro, Italy), have built on recent advances to grow 'mini-organs' in a laboratory, known as organoids.
A number of new technologies and surgical techniques promise to "personalize" orthopedic operations such as hip and knee replacement, according to research to be presented at an educational program at Hospital for Special Surgery on October 15 and 16. During "Computer Assisted Orthopaedic Surgery: Review of Emerging Technologies," prominent orthopedic researchers will discuss how innovative technologies can improve surgical outcomes.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $650 |
Number of Payment Denials | 1 |
Total Number of Penalties | 2 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 28.19 | 14.46 |
Percentage of long-stay residents who lose too much weight | 9.45 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50.67 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 9.15 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 11.33 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.32 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.29 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 10 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 30.32 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.64 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 3.41 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.86 | 95.98 |